China National Medicines (SHSE:600511) Other Stockholders Equity: ¥2,005 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600511 China National Medicines Corp Ltd SHSE:600511
90 GF Score
Price ¥26.77
GF Value ¥32.09
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China National Medicines Other Stockholders Equity?

China National Medicines SHSE:600511 -0.04% 90 Other Stockholders Equity is ¥2,005 Mil as of Jun. 2026. GuruFocus rates SHSE:600511 with a GF Score™ of 90/100 and a GF Value™ of ¥32.09 (Modestly Undervalued). The stock has 3 warning signs investors should review.

China National Medicines's Other Stockholders Equity for the quarter that ended in Jun. 2026 was ¥2,005 Mil.

China National Medicines's quarterly Other Stockholders Equity increased from Dec. 2025 (¥2,015 Mil) to Mar. 2026 (¥3,034 Mil) but then declined from Mar. 2026 (¥3,034 Mil) to Jun. 2026 (¥2,005 Mil).

China National Medicines's annual Other Stockholders Equity declined from Dec. 2023 (¥1,995 Mil) to Dec. 2024 (¥1,992 Mil) but then increased from Dec. 2024 (¥1,992 Mil) to Dec. 2025 (¥2,015 Mil).

China National Medicines Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for China National Medicines's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China National Medicines Other Stockholders Equity Chart

China National Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,989.77 1,988.88 1,995.42 1,991.84 2,015.48

China National Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,992.18 3,009.27 2,015.48 3,034.20 2,004.87
SHSE:600511
90GF Score
China National Medicines Corp Ltd SHSE:600511
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China National Medicines Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥2,005 Mil mean?
China National Medicines (SHSE:600511) has a Other Stockholders Equity of ¥2,005 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on China National Medicines and its competitors.
Is China National Medicines' Other Stockholders Equity too high?
China National Medicines' current Other Stockholders Equity is ¥2,005 Mil. Overall, China National Medicines has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Other Stockholders Equity compare to MCK and COR?
China National Medicines' Other Stockholders Equity of ¥2,005 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Distribution company?
A good Other Stockholders Equity depends on the Medical Distribution industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on China National Medicines and its competitors. China National Medicines's current Other Stockholders Equity is ¥2,005 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.09, compared to a current price of ¥26.77 — trading 16.6% below its estimated fair value. The current Other Stockholders Equity is ¥2,005 Mil. China National Medicines' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Other Stockholders Equity is ¥2,005 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China National Medicines (SHSE:600511) Overvalued in 2026?

Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued. The current stock price of ¥26.77 is trading 16.6% below its estimated GF Value™ of ¥32.09. GuruFocus considers China National Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:600511:

  • Other Stockholders Equity: ¥2,005 Mil
  • GF Value™: ¥32.09 vs. price of ¥26.77 (16.6% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China National Medicines Business Description

Address No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
90GF Score

Get the complete analysis for SHSE:600511

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.77
Price
¥32.09
GF Value